您的位置: 首页 > 农业专利 > 详情页

T CELL-BASED IMMUNOTHERAPEUTICS
专利权人:
BCRT HOLDING BV
发明人:
DE BOER, MARK,LINNEMANN, CARSTEN,SCHUMACHER, ANTONIUS NICOLAAS MARIA,MEZZADRA, RICCARDO
申请号:
CA2965224
公开号:
CA2965224A1
申请日:
2015.10.26
申请国别(地区):
CA
年份:
2016
代理人:
摘要:
The present invention provides compositions and methods for immunotherapy in human. The invention includes a B cell receptor like complex expressed in T cells and comprising an extracellular antigen recognition domain, a trans-membrane domain, a CD79aß heterodimer, and a signaling region that controls T cell activation. The extracellular antigen recognition domain and trans-membrane are derived from the same human or humanized B cell receptor and form a single unit in the complex. The signaling region comprises a T cell signaling domain in combination with a co-stimulatory signaling domain. The signaling region is fused to the CD79aß heterodimer. Furthermore, the B cell receptor like complex of the present invention can use a targeting molecule as a bridge between cytotoxic T cells and targeted cells.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充